temozolomide has been researched along with Blood Diseases in 24 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Temozolomide (TMZ) administered daily with radiation therapy (RT) for 6 weeks, followed by adjuvant TMZ for 6 cycles, is the standard therapy for newly diagnosed glioblastoma (GBM) patients." | 9.20 | Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment: A Prospective Study. ( Amadori, A; Berti, F; Bertorelle, R; Della Puppa, A; Farina, P; Lombardi, G; Marcato, R; Rumiato, E; Sacchetto, V; Saggioro, D; Zagonel, V; Zustovich, F, 2015) |
| "The aim of this prospective and multicentric phase II study was to evaluate the efficacy and safety of temozolomide (TMZ) and bevacizumab (BV) in patients (pts) with recurrent glioblastoma (GB), previously treated with chemoradiotherapy and at least three cycles of adjuvant TMZ." | 9.20 | A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma. ( Balañá, C; Belda-Iniesta, C; Berrocal, A; Capellades, J; Gallego, O; Gil-Gil, M; La Orden, B; Ordoñez, JM; Pérez-Segura, P; Reynés, G; Sepúlveda, JM, 2015) |
| "Based on the promising results of a Phase I study with a combination of gemcitabine and DTIC performed in advanced soft tissue sarcoma (ASTS) patients, and due to the limited efficacy of second or third line therapies in those patients, we designed a Phase II study to determine the activity of this new regimen." | 9.12 | Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. ( Buesa, JM; Del Muro, JG; Escudero, P; Esteban, E; Fra, J; Gión, M; Goitia, A; López-Pousa, A; Losa, R; Maurel, J; Nadal, R; Sierra, M; Uña, E, 2007) |
| "Twenty-one patients with recurrent or progressive glioblastoma were enrolled in a prospective phase II trial to determine the safety and efficacy of a 1-week on/1-week off regimen of temozolomide administered at 150 mg/m2 on days 1 to 7 and days 15 to 21 of 28-day treatment cycles." | 9.11 | One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. ( Bamberg, M; Dichgans, J; Küker, WM; Steinbach, JP; Weller, M; Wick, W, 2004) |
| "Temozolomide (Temodar) has demonstrated clinical activity against melanoma equivalent to that of intravenous dacarbazine (DTIC)." | 9.10 | Phase II evaluation of temozolomide in metastatic choroidal melanoma. ( Bedikian, AY; Eton, O; Papadopoulos, N; Plager, C; Ring, S, 2003) |
| "The temozolomide is a promising orally cytotoxic agent used in malignant glioma." | 8.83 | The safety of the temozolomide in patients with malignant glioma. ( Dario, A; Tomei, G, 2006) |
| "This study was performed to validate the effectiveness and safety of concurrent chemoradiotherapy and adjuvant therapy with temozolomide for newly diagnosed glioblastoma multiforme as a standard treatment protocol." | 7.81 | Validation of the Effectiveness and Safety of Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas: 10-year Experience of a Single Institution. ( Han, JH; Joo, JD; Kim, CY; Kim, H; Kim, YH, 2015) |
| "Radiation therapy with concomitant and adjuvant temozolomide (TMZ) is the standard therapy for nonelderly patients with glioblastoma." | 7.80 | Toxicity and outcome of radiotherapy with concomitant and adjuvant temozolomide in elderly patients with glioblastoma: a retrospective study. ( Mukasa, A; Narita, Y; Saito, K; Saito, N; Shibui, S; Shinoura, N; Tabei, Y, 2014) |
| "This study evaluated the toxicity profiles of temozolomide in the treatment of malignant glioma as either concurrent or adjuvant chemotherapy." | 7.80 | Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea. ( Bae, SH; Cho, SY; Kim, CY; Kim, TM; Kim, YH; Kim, YJ; Lee, MM; Lee, SH; Park, CK; Park, MJ, 2014) |
| "Temozolomide has significantly improved the outcome of patients with glioblastoma." | 7.77 | [Benefit of a prolonged adjuvant treatment with temozolomide for the management of patients with glioblastoma]. ( Auberdiac, P; Cartier, L; Chargari, C; Forest, F; Fotso, MJ; Magné, N; Malkoun, N; Nuti, C; Pacaut, C; Peoc'h, M; Schmitt, T; Thorin, J, 2011) |
| "A retrospective analysis of the toxicity and efficacy of temozolomide in advanced neuroendocrine tumors." | 7.74 | Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. ( Dunder, K; Ekeblad, S; Eriksson, B; Granberg, D; Janson, ET; Kindmark, H; Kozlovacki, G; Oberg, K; Orlefors, H; Sigurd, M; Skogseid, B; Sundin, A; Welin, S, 2007) |
| "Glioblastoma is the most common and aggressive primitive brain tumor in adults." | 5.48 | Good tolerability of maintenance temozolomide in glioblastoma patients after severe hematological toxicity during concomitant radiotherapy and temozolomide treatment: report of two cases. ( Bellu, L; Bergo, E; Berti, F; Caccese, M; Dal Pos, S; Della Puppa, A; Denaro, L; Gardiman, MP; Lombardi, G; Pambuku, A; Zagonel, V, 2018) |
| " In the present analysis, we retrospectively investigated the feasibility and effectiveness of bevacizumab combined with ICE in patients with glioblastoma at second relapse during ICE treatment." | 5.39 | Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma. ( Arakawa, Y; Fujimoto, K; Kikuchi, T; Kunieda, T; Miyamoto, S; Mizowaki, T; Murata, D; Takagi, Y; Takahashi, JC, 2013) |
| "Temozolomide (TMZ) administered daily with radiation therapy (RT) for 6 weeks, followed by adjuvant TMZ for 6 cycles, is the standard therapy for newly diagnosed glioblastoma (GBM) patients." | 5.20 | Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment: A Prospective Study. ( Amadori, A; Berti, F; Bertorelle, R; Della Puppa, A; Farina, P; Lombardi, G; Marcato, R; Rumiato, E; Sacchetto, V; Saggioro, D; Zagonel, V; Zustovich, F, 2015) |
| "The aim of this prospective and multicentric phase II study was to evaluate the efficacy and safety of temozolomide (TMZ) and bevacizumab (BV) in patients (pts) with recurrent glioblastoma (GB), previously treated with chemoradiotherapy and at least three cycles of adjuvant TMZ." | 5.20 | A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma. ( Balañá, C; Belda-Iniesta, C; Berrocal, A; Capellades, J; Gallego, O; Gil-Gil, M; La Orden, B; Ordoñez, JM; Pérez-Segura, P; Reynés, G; Sepúlveda, JM, 2015) |
| "Based on the promising results of a Phase I study with a combination of gemcitabine and DTIC performed in advanced soft tissue sarcoma (ASTS) patients, and due to the limited efficacy of second or third line therapies in those patients, we designed a Phase II study to determine the activity of this new regimen." | 5.12 | Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. ( Buesa, JM; Del Muro, JG; Escudero, P; Esteban, E; Fra, J; Gión, M; Goitia, A; López-Pousa, A; Losa, R; Maurel, J; Nadal, R; Sierra, M; Uña, E, 2007) |
| "Twenty-one patients with recurrent or progressive glioblastoma were enrolled in a prospective phase II trial to determine the safety and efficacy of a 1-week on/1-week off regimen of temozolomide administered at 150 mg/m2 on days 1 to 7 and days 15 to 21 of 28-day treatment cycles." | 5.11 | One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. ( Bamberg, M; Dichgans, J; Küker, WM; Steinbach, JP; Weller, M; Wick, W, 2004) |
| "Temozolomide (Temodar) has demonstrated clinical activity against melanoma equivalent to that of intravenous dacarbazine (DTIC)." | 5.10 | Phase II evaluation of temozolomide in metastatic choroidal melanoma. ( Bedikian, AY; Eton, O; Papadopoulos, N; Plager, C; Ring, S, 2003) |
| "In patients with glioblastoma multiforme (GBM), there is no consensus on the sequential use of two existing regimens: post-operative Gliadel implantation into the surgical cavity and concomitant temozolomide with radiotherapy followed by adjuvant temozolomide ('Stupp protocol')." | 4.87 | The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review. ( Achawal, S; Dixit, S; Hingorani, M; Scott, I, 2011) |
| "The temozolomide is a promising orally cytotoxic agent used in malignant glioma." | 4.83 | The safety of the temozolomide in patients with malignant glioma. ( Dario, A; Tomei, G, 2006) |
| "This study was performed to validate the effectiveness and safety of concurrent chemoradiotherapy and adjuvant therapy with temozolomide for newly diagnosed glioblastoma multiforme as a standard treatment protocol." | 3.81 | Validation of the Effectiveness and Safety of Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas: 10-year Experience of a Single Institution. ( Han, JH; Joo, JD; Kim, CY; Kim, H; Kim, YH, 2015) |
| "Radiation therapy with concomitant and adjuvant temozolomide (TMZ) is the standard therapy for nonelderly patients with glioblastoma." | 3.80 | Toxicity and outcome of radiotherapy with concomitant and adjuvant temozolomide in elderly patients with glioblastoma: a retrospective study. ( Mukasa, A; Narita, Y; Saito, K; Saito, N; Shibui, S; Shinoura, N; Tabei, Y, 2014) |
| "This study evaluated the toxicity profiles of temozolomide in the treatment of malignant glioma as either concurrent or adjuvant chemotherapy." | 3.80 | Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea. ( Bae, SH; Cho, SY; Kim, CY; Kim, TM; Kim, YH; Kim, YJ; Lee, MM; Lee, SH; Park, CK; Park, MJ, 2014) |
| "A retrospective analysis was conducted to identify patients (N=117) who received standard oral temozolomide for glioblastoma at our institution from 2003 to 2010." | 3.79 | An automated system for detecting nonadherence in laboratory testing and monitoring for myelosuppression in patients receiving self-administered oral chemotherapy. ( Carter, AF; DeTroye, AT; Harmon, MS; Lesser, GJ; Morrell, RM; Tooze, JA, 2013) |
| "Temozolomide has significantly improved the outcome of patients with glioblastoma." | 3.77 | [Benefit of a prolonged adjuvant treatment with temozolomide for the management of patients with glioblastoma]. ( Auberdiac, P; Cartier, L; Chargari, C; Forest, F; Fotso, MJ; Magné, N; Malkoun, N; Nuti, C; Pacaut, C; Peoc'h, M; Schmitt, T; Thorin, J, 2011) |
| "A retrospective analysis of the toxicity and efficacy of temozolomide in advanced neuroendocrine tumors." | 3.74 | Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. ( Dunder, K; Ekeblad, S; Eriksson, B; Granberg, D; Janson, ET; Kindmark, H; Kozlovacki, G; Oberg, K; Orlefors, H; Sigurd, M; Skogseid, B; Sundin, A; Welin, S, 2007) |
| "The results suggest that Cyberknife re-treatments are relatively safe using selected dose/fraction schemes." | 2.77 | Efficacy and toxicity of CyberKnife re-irradiation and "dose dense" temozolomide for recurrent gliomas. ( Arpa, D; Cardali, S; Conti, A; De Renzis, C; Granata, F; Pontoriero, A; Romanelli, P; Siragusa, C; Tomasello, C; Tomasello, F, 2012) |
| "Temozolomide was administered orally, daily for 5 days starting at 28 mg/m(2) per day with escalations to 40, 55, 75 and 100 mg/m(2) per day with O(6)BG intravenously daily for 5 days at doses of 60, 90 or 120 mg/m(2) per day." | 2.74 | Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors. ( Aikin, AA; Balis, FM; Cole, DE; Fox, E; Meany, HJ; Warren, KE, 2009) |
| "Because of the diffuse nature of gliomatosis cerebri (GC), surgery is not suitable, and large field radiotherapy carries the risk of severe toxicity." | 2.71 | Initial chemotherapy in gliomatosis cerebri. ( Carpentier, A; Cartalat-Carel, S; Chinot, O; Cougnard, J; Delattre, JY; Djafari, L; Duffau, H; Gervais, H; Hoang-Xuan, K; Honnorat, J; Laigle, F; Mokhtari, K; Napolitano, M; Sanson, M; Taillandier, L; Taillibert, S, 2004) |
| " However severe hematologic adverse events (HAEs), including myelodysplastic syndrome and aplastic anemia, have also been reported." | 2.49 | Temozolomide-related hematologic toxicity. ( De Sanctis, V; Enrici, RM; Minniti, G; Scaringi, C, 2013) |
| "Glioblastoma is the most common and aggressive primitive brain tumor in adults." | 1.48 | Good tolerability of maintenance temozolomide in glioblastoma patients after severe hematological toxicity during concomitant radiotherapy and temozolomide treatment: report of two cases. ( Bellu, L; Bergo, E; Berti, F; Caccese, M; Dal Pos, S; Della Puppa, A; Denaro, L; Gardiman, MP; Lombardi, G; Pambuku, A; Zagonel, V, 2018) |
| " In the present analysis, we retrospectively investigated the feasibility and effectiveness of bevacizumab combined with ICE in patients with glioblastoma at second relapse during ICE treatment." | 1.39 | Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma. ( Arakawa, Y; Fujimoto, K; Kikuchi, T; Kunieda, T; Miyamoto, S; Mizowaki, T; Murata, D; Takagi, Y; Takahashi, JC, 2013) |
| "Temozolomide (TMZ) is a widely used oral alkylating agent that has been associated with the development of severe hematologic adverse events (HAEs)." | 1.38 | Hematologic adverse events associated with temozolomide. ( Abdur, S; Bressler, LR; Letarte, N; Villano, JL; Yu, JM, 2012) |
| "Temozolomide was administered at a dose of 200 mg/m(2) daily for 5 days, in a 4-week cycle." | 1.34 | Temozolomide in pediatric low-grade glioma. ( Ashley, DM; Coleman, LT; Downie, PA; Heath, JA; Khaw, SL, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (37.50) | 29.6817 |
| 2010's | 15 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardi, G | 2 |
| Caccese, M | 1 |
| Bellu, L | 1 |
| Pambuku, A | 1 |
| Bergo, E | 1 |
| Berti, F | 2 |
| Gardiman, MP | 1 |
| Della Puppa, A | 2 |
| Denaro, L | 1 |
| Dal Pos, S | 1 |
| Zagonel, V | 2 |
| Gupta, T | 1 |
| Mohanty, S | 1 |
| Moiyadi, A | 1 |
| Jalali, R | 1 |
| Scaringi, C | 1 |
| De Sanctis, V | 1 |
| Minniti, G | 1 |
| Enrici, RM | 1 |
| Morrell, RM | 1 |
| Tooze, JA | 1 |
| Harmon, MS | 1 |
| Carter, AF | 1 |
| DeTroye, AT | 1 |
| Lesser, GJ | 1 |
| Rumiato, E | 1 |
| Bertorelle, R | 1 |
| Saggioro, D | 1 |
| Farina, P | 1 |
| Zustovich, F | 1 |
| Sacchetto, V | 1 |
| Marcato, R | 1 |
| Amadori, A | 1 |
| Arakawa, Y | 1 |
| Mizowaki, T | 1 |
| Murata, D | 1 |
| Fujimoto, K | 1 |
| Kikuchi, T | 1 |
| Kunieda, T | 1 |
| Takahashi, JC | 1 |
| Takagi, Y | 1 |
| Miyamoto, S | 1 |
| Saito, K | 1 |
| Mukasa, A | 1 |
| Narita, Y | 1 |
| Tabei, Y | 1 |
| Shinoura, N | 1 |
| Shibui, S | 1 |
| Saito, N | 1 |
| Kesavan, M | 1 |
| Claringbold, PG | 1 |
| Turner, JH | 1 |
| Bae, SH | 1 |
| Park, MJ | 1 |
| Lee, MM | 1 |
| Kim, TM | 1 |
| Lee, SH | 1 |
| Cho, SY | 1 |
| Kim, YH | 2 |
| Kim, YJ | 1 |
| Park, CK | 1 |
| Kim, CY | 2 |
| Sepúlveda, JM | 1 |
| Belda-Iniesta, C | 1 |
| Gil-Gil, M | 1 |
| Pérez-Segura, P | 1 |
| Berrocal, A | 1 |
| Reynés, G | 1 |
| Gallego, O | 1 |
| Capellades, J | 1 |
| Ordoñez, JM | 1 |
| La Orden, B | 1 |
| Balañá, C | 1 |
| Joo, JD | 1 |
| Kim, H | 1 |
| Han, JH | 1 |
| Dario, A | 1 |
| Tomei, G | 1 |
| Meany, HJ | 1 |
| Warren, KE | 1 |
| Fox, E | 1 |
| Cole, DE | 1 |
| Aikin, AA | 1 |
| Balis, FM | 1 |
| Dixit, S | 1 |
| Hingorani, M | 1 |
| Achawal, S | 1 |
| Scott, I | 1 |
| Malkoun, N | 1 |
| Fotso, MJ | 1 |
| Cartier, L | 1 |
| Forest, F | 1 |
| Auberdiac, P | 1 |
| Chargari, C | 1 |
| Thorin, J | 1 |
| Pacaut, C | 1 |
| Peoc'h, M | 1 |
| Nuti, C | 1 |
| Schmitt, T | 1 |
| Magné, N | 1 |
| Villano, JL | 1 |
| Letarte, N | 1 |
| Yu, JM | 1 |
| Abdur, S | 1 |
| Bressler, LR | 1 |
| Conti, A | 1 |
| Pontoriero, A | 1 |
| Arpa, D | 1 |
| Siragusa, C | 1 |
| Tomasello, C | 1 |
| Romanelli, P | 1 |
| Cardali, S | 1 |
| Granata, F | 1 |
| De Renzis, C | 1 |
| Tomasello, F | 1 |
| Bedikian, AY | 1 |
| Papadopoulos, N | 1 |
| Plager, C | 1 |
| Eton, O | 1 |
| Ring, S | 1 |
| Wick, W | 1 |
| Steinbach, JP | 1 |
| Küker, WM | 1 |
| Dichgans, J | 1 |
| Bamberg, M | 1 |
| Weller, M | 1 |
| Sanson, M | 1 |
| Cartalat-Carel, S | 1 |
| Taillibert, S | 1 |
| Napolitano, M | 1 |
| Djafari, L | 1 |
| Cougnard, J | 1 |
| Gervais, H | 1 |
| Laigle, F | 1 |
| Carpentier, A | 1 |
| Mokhtari, K | 1 |
| Taillandier, L | 1 |
| Chinot, O | 1 |
| Duffau, H | 1 |
| Honnorat, J | 1 |
| Hoang-Xuan, K | 1 |
| Delattre, JY | 1 |
| Wong, ET | 1 |
| Losa, R | 1 |
| Fra, J | 1 |
| López-Pousa, A | 1 |
| Sierra, M | 1 |
| Goitia, A | 1 |
| Uña, E | 1 |
| Nadal, R | 1 |
| Del Muro, JG | 1 |
| Gión, M | 1 |
| Maurel, J | 1 |
| Escudero, P | 1 |
| Esteban, E | 1 |
| Buesa, JM | 1 |
| Ekeblad, S | 1 |
| Sundin, A | 1 |
| Janson, ET | 1 |
| Welin, S | 1 |
| Granberg, D | 1 |
| Kindmark, H | 1 |
| Dunder, K | 1 |
| Kozlovacki, G | 1 |
| Orlefors, H | 1 |
| Sigurd, M | 1 |
| Oberg, K | 1 |
| Eriksson, B | 1 |
| Skogseid, B | 1 |
| Khaw, SL | 1 |
| Coleman, LT | 1 |
| Downie, PA | 1 |
| Heath, JA | 1 |
| Ashley, DM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Trial and Pharmacokinetic Study of Temozolomide and O6-Benzylguanine in Childhood Solid Tumors[NCT00020150] | Phase 1 | 0 participants | Interventional | 2000-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for temozolomide and Blood Diseases
| Article | Year |
|---|---|
Temozolomide-related hematologic toxicity.
Topics: Antineoplastic Agents, Alkylating; Comorbidity; Dacarbazine; Drug-Related Side Effects and Adverse R | 2013 |
The safety of the temozolomide in patients with malignant glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Child; Clinical Trials as Topic; Dacarbazine; Drug Interac | 2006 |
The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Car | 2011 |
9 trials available for temozolomide and Blood Diseases
| Article | Year |
|---|---|
Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment: A Prospective Study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; | 2015 |
Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Blood Platelets; Capecitabine; Dacarbazine; Deoxycytidin | 2014 |
A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Dacarbazi | 2015 |
Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Ch | 2009 |
Efficacy and toxicity of CyberKnife re-irradiation and "dose dense" temozolomide for recurrent gliomas.
Topics: Antineoplastic Agents, Alkylating; Asthenia; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Fe | 2012 |
Phase II evaluation of temozolomide in metastatic choroidal melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Choroid Neoplasms; Dacarbazine; Female; | 2003 |
One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Disease Prog | 2004 |
Initial chemotherapy in gliomatosis cerebri.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2004 |
Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; | 2007 |
12 other studies available for temozolomide and Blood Diseases
| Article | Year |
|---|---|
Good tolerability of maintenance temozolomide in glioblastoma patients after severe hematological toxicity during concomitant radiotherapy and temozolomide treatment: report of two cases.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Glioblastoma; Hematol | 2018 |
Factors predicting temozolomide induced clinically significant acute hematologic toxicity in patients with high-grade gliomas: a clinical audit.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Community-Acquired | 2013 |
An automated system for detecting nonadherence in laboratory testing and monitoring for myelosuppression in patients receiving self-administered oral chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Blood Cell Count; Brain Neopla | 2013 |
Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Toxicity and outcome of radiotherapy with concomitant and adjuvant temozolomide in elderly patients with glioblastoma: a retrospective study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradio | 2014 |
Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents, Alkylating; Brain Neopl | 2014 |
Validation of the Effectiveness and Safety of Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas: 10-year Experience of a Single Institution.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chem | 2015 |
[Benefit of a prolonged adjuvant treatment with temozolomide for the management of patients with glioblastoma].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2011 |
Hematologic adverse events associated with temozolomide.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents, Alkylating; Dacarbazine; Databases, | 2012 |
Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2005 |
Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors.
Topics: Aged; Bronchial Neoplasms; Carcinoid Tumor; Dacarbazine; Female; Hematologic Diseases; Humans; Male; | 2007 |
Temozolomide in pediatric low-grade glioma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplati | 2007 |